MiR-125b promotes cell migration and invasion by targeting PPP1CA-Rb signal pathways in gastric cancer, resulting in a poor prognosis

Wu, Jianguo; Jinjie, Wang; Jiang, Xin; Lan, Jianping; He, Xu; Wang, Hui-Ju; Ma, Yingyu; Xia, Yingjie; Ru, Guoqing; Ma, Jie; Zhao, Zhenze; Ren, Zhimin

doi:10.1007/s10120-014-0421-8

Cited by 64 publications

(63 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there have been progress in treatment, the prognosis for GC remains unsatisfactory [2]. Thus, it is of great significance to further exploration of the molecular mechanisms underlying the initiation of GC to promote the advancement of novel and efficient therapeutic targets for treatment.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‐339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1

Shen

Zhang

et al. 2015

FEBS Letters

View full text Add to dashboard Cite

a b s t r a c tThe role of miR-339 in human gastric cancer (GC) remains unclear. Here, we found that miR-339 is remarkably decreased in primary GC tissues. Overexpression of miR-339 in GC cells significantly suppressed proliferation, migration, invasion, and tumorigenicity. Furthermore, NOVA1 was confirmed as a target of miR-339. Restoration of NOVA1 in miR-339-overexpressing GC cells partially impaired the inhibitory effects of miR-339. More importantly, epigenetic modification may be involved in the modulation of miR-339 expression. These findings uncover a novel role for miR-339 in gastric carcinogenesis, and restoration of miR-339 could be considered as a potential therapeutic strategy for GC treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA‐339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1

Shen

Zhang

et al. 2015

FEBS Letters

View full text Add to dashboard Cite

show abstract

“…Deregulation of miRNAs has been detected in numerous types of cancer, including RCC and gastric cancer (11,16), and has been confirmed to be capable of promoting cancer initiation and progression (11), a number of which function as oncogenes or tumor suppressors, depending on the differences of the targeted gene. The expression of miR-125b has been revealed to be deregulated in a number of types of cancer, including gastric cancer (16), non-small-cell lung cancer (NSCLC) (19) and osteosarcoma (12).…”

Section: Discussionmentioning

confidence: 99%

“…The function of miR-125b in a number of cancer subtypes, including osteosarcoma and gastric cancer, was explored (15,16). In osteosarcoma, miR-125b was described as a tumor suppressor (15), and in gastric cancer, miR-125b functions as an oncogene (16).…”

Section: Introductionmentioning

confidence: 99%

miR-125b is associated with renal cell carcinoma cell migration, invasion and apoptosis

Jin

Zeng

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. MicroRNA (miR)-125b has been identified as deregulated in a number of types of cancer. Previous studies have detected the expression of miR-125b in clear cell renal cell carcinoma (ccRCC) tissues by in situ hybridization and revealed that miR-125b was upregulated in ccRCC tissues, and was associated with recurrence and survival of patients with ccRCC. However, the function of miR-125b in RCC remains unclear. Thus, the expression of miR-125b was detected with quantitative polymerase chain reaction (qPCR) in 24 paired RCC and adjacent normal tissues. The result of qPCR showed that miR-125b was upregulated in RCC tissues. Furthermore, the function of miR-125b in RCC (786-O and ACHN) cells was detected by transfecting miR-125 mimic or inhibitor to upregulate or downregulate miR-125b expression. Cell proliferation assays (MTT and Cell Counting Kit-8), cell mobility assays (cell scratch and Transwell assay) and a cell apoptotic assay (flow cytometry assay) were performed to assess the function of miR-125b on RCC cells. Results from the assays demonstrated that overexpression of miR-125b could promote cell migration and invasion, and reduce the cell apoptotic rate. It was also revealed that downregulation of miR-125b could reduce cell migration and invasion, and induce cell apoptosis. However, the results of the cell proliferation assay revealed that miR-125b had no significant effect on cell proliferation. Not only could miR-125b predict recurrence and survival of ccRCC; the present study revealed that miR-125b could regulate RCC cell migration, invasion and apoptosis. Additional studies are required to determine the mechanism of miR-125b in RCC cells and define the target genes of miR-125b in RCC.

show abstract

“…A number of studies suggested that miR-125b was a novel prognostic marker for patients with liver cancer, gastric cancer, colorectal cancer, lung cancer, or glioma [7][8][9][10][11]. Additionally, some studies further reported that miR-125b was related to cell migration, invasion, and therapeutic resistance in gastric cancer and breast cancer [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

“…At present, some chromosomal abnormalities, such as t (15,17), t (8,21), t(11q23), and inv(16)/t (16; 16), have been identified, and these abnormalities show specific clinical and prognostic significance in AML [1]. Accord-DOI: 10.1159/000491584 ing to these cytogenetic findings, the disease is classified into 3 cytogenetic risk groups (favorable, intermediate and poor) [3].…”

Section: Introductionmentioning

confidence: 99%

Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia

et al. 2018

View full text Add to dashboard Cite

Background: The prognostic significance of miR-125b in intermediate-risk acute myeloid leukemia has not been well investigated. The aim of the study was to reveal the relationship between the elevated exosomal miR-125b level and the poor prognosis in adult patients with this disease. Methods: A total of 154 consecutive patients with intermediate-risk acute myeloid leukemia were enrolled. Exosomes were isolated from blood specimens. The exosomal miR-125b level was determined using quantitative real-time polymerase chain reaction. Patients received standardized therapy and were followed up for 1–24 months. Details about relapse and overall death were recorded. Results: Patients were divided into the high miR-125b level group (n = 77) and the low miR-125b level group (n = 77). In the multivariate Cox proportional hazard regression model, the high miR-125b level group was separately associated with increased risks of relapse and overall death in 2 years (hazard ratio [HR] 2.84, 95% CI 1.81–4.33 and HR 2.69, 95% CI 1.87–4.52). Kaplan-Meier analysis also revealed that a high miR-125b level was related to a higher cumulative relapse and overall death rates (p < 0.001 and p < 0.001, respectively). Conclusion: Circulating exosomal miR-125b concentration might be an independent prognostic indicator in intermediate-risk acute myeloid leukemia patients. An elevated miR-125b level indicated higher risks of relapse and overall death.

show abstract

MiR-125b promotes cell migration and invasion by targeting PPP1CA-Rb signal pathways in gastric cancer, resulting in a poor prognosis

Cited by 64 publications

References 30 publications

MicroRNA‐339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1

MicroRNA‐339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1

miR-125b is associated with renal cell carcinoma cell migration, invasion and apoptosis

Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia

Contact Info

Product

Resources

About